Indeed, clinical studies found that ROP infants treated with the anti-VEGF drug bevacizumab were associated with lower motor scores and higher rates of severe neurodevelopmental disability in comparison with laser treatment 18 months post treatment [11]. Here, VEGFA is linked to retinopathy of prematurity.